2. De Leo V, Musacchio MC, Cappelli V, Piomboni P, Morgante G. Hormonal contraceptives: pharmacology tailored to women’s health. Hum Reprod Update 2016;22:634-46.
3. Kim JS, Cho S. Clinical use of oral contraceptives. J Korean Med Assoc 2017;60:687-93.
4. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5:692-9.
5. US Food and Drug Administration. FDA Drug Safety Communication: updated information about the risk of blood clots in women taking birth control pills containing drospirenone [Internet] Silver Spring (MD): US Food and Drug Administration; c2012 [cited 2015 July 17]. Available from:
http://www.fda.gov/Drugs/DrugSafety/ucm299305.htm
.
6. Helmerhorst FM, Rosendaal FR. Is an EMA review on hormonal contraception and thrombosis needed? BMJ 2013;346:f1464.
8. Fruzzetti F, Perini D, Spirito N, Manca R. Oral contraceptive pill and thrombotic risk: epidemiological studies. Minerva Ginecol 2012;64:539-49.
9. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001;344:1527-35.
10. Bae SH, Kim KH, Whang JY, Lee JM, Kim JM, Ku JM, et al. Treatment by transradial urokinase infusion and percutaneous transhepatic thrombectomy in superior mesenteric veno us thrombosis with intestinal infarction. Korean J Med 2018;93:55-60.
13. Yeo MS, Kwon YS, Choi SH, Kim KH, Byun CG, Koh YT, et al. SMV thrombosis on taking oral contraceptive with protein C and protein S deficiency. Ann Surg Treat Res 2006;71:222-5.
14. Park JH, Yang JH, Yoo DS, Cho KS, Huh PW, Kwon SO, et al. Deep cerebral venous thrombosis: successful treatment by systemic urokinase followed by heparin: case report. J Korean Neurosurg Soc 2001;30:99-104.
15. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-80.
19. Conard J. Biological coagulation findings in third-generation oral contraceptives. Hum Reprod Update 1999;5:672-80.
20. Bladbjerg EM, Skouby SO, Andersen LF, Jespersen J. Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. Hum Reprod 2002;17:3235-41.
21. Suzuki A, Sanda N, Miyawaki Y, Fujimori Y, Yamada T, Takagi A, et al. Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex. J Biol Chem 2010;285:13444-53.
22. Ali HO, Stavik B, Dørum E, Iversen N, Sandset PM, Skretting G. Oestrogen induced downregulation of TFPI expression is mediated by ERα. Thromb Res 2014;134:138-43.
23. Hughes Q, Watson M, Cole V, Sayer M, Baker R, Staton J. Upregulation of protein S by progestins. J Thromb Haemost 2007;5:2243-9.
24. Kozuka T, Tamura S, Kawamura N, Nakata Y, Hasebe R, Makiyama A, et al. Progestin isoforms provide different levels of protein S expression in HepG2 cells. Thromb Res 2016;145:40-5.
25. Lee SH, Lee IY, Kim EA. Experience of taking oral contraceptives in adult women. Korean J Women Health Nurs 2017;23:265-75.
26. Kobayashi T, Sugiura K, Ojima T. Risks of thromboembolism associated with hormone contraceptives in Japanese compared with Western women. J Obstet Gynaecol Res 2017;43:789-97.
27. Sugiura K, Kobayashi T, Ojima T. Risks of thromboembolism associated with hormonal contraceptives related to body mass index and aging in Japanese women. Thromb Res 2016;137:11-6.
29. Lidegaard Ø. Smoking and use of oral contraceptives: impact on thrombotic diseases. Am J Obstet Gynecol 1999;180(6 Pt 2):S357-63.
30. Roy S. Effects of smoking on prostacyclin formation and platelet aggregation in users of oral contraceptives. Am J Obstet Gynecol 1999;180(6 Pt 2):S364-8.
31. Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002;65:187-96.
34. Hugon-Rodin J, Gompel A, Plu-Bureau G. Epidemiology of hormonal contraceptives-related venous thromboembolism. Eur J Endocrinol 2014;171:R221-30.
35. Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol 2007;6:162-70.
36. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA 2000;284:72-8.
37. Dentali F, Crowther M, Ageno W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood 2006;107:2766-73.
38. Le Gal G, Kovacs MJ, Carrier M, Do K, Kahn SR, Wells PS, et al. Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study. Thromb Haemost 2010;104:498-503.
39. Kearon C, Spencer FA, O’Keeffe D, Parpia S, Schulman S, Baglin T, et al. D-dimer Optimal Duration Study Investigators. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med 2015;162:27-34.
40. Blanco-Molina Á, Trujillo-Santos J, Pesavento R, Rosa V, Falgá C, Tolosa C, et al. Outcome after discontinuing anticoagulant therapy in women with venous thromboembolism during hormonal use. Thromb Res 2017;151(Suppl 1):S6-10.